Supernus Pharma (SUPN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Supernus Announces Fourth Quarter and Full Year 2014 Results
March 10, 2015 5:00 PM EDTCash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million. Â Net income for the fourth quarter, $4.4 million, and for the full year, $19.9 million. Â Total revenue for the fourth quarter, $30.8 million, exceeded guidance by $4 million, and includes $30.5 million in net product sales. Â Total revenue for full year 2014 was $122.0 million, including $89.6 million in net product sales. Â Fourth quarter product prescriptions increased to 70,739, representing a 22% increase over the third quarter of 2014. Â Met with the FDA in December to review SPN-810. We remain on-track to initiate Phase III testing in the fourth quarter of... More
Supernus Announces Fourth Quarter and Full Year 2014 Results
March 10, 2015 5:00 PM EDTCash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million. Â Net income for the fourth quarter, $4.4 million, and for the full year, $19.9 million. Â Total revenue for the fourth quarter, $30.8 million, exceeded guidance by $4 million, and includes $30.5 million in net product sales. Â Total revenue for full year 2014 was $122.0 million, including $89.6 million in net product sales. Â Fourth quarter product prescriptions increased to 70,739, representing a 22% increase over the third quarter of 2014. Â Met with the FDA in December to review SPN-810. We remain on-track to initiate Phase III testing in the fourth quarter of... More
